


PHARMACEUTICAL 2017



ALIMERA SCIENCES INC Rank 154 of 313





PHARMACEUTICAL 2017

ALIMERA SCIENCES INC Rank 154 of 313



The relative strengths and weaknesses of ALIMERA SCIENCES INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALIMERA SCIENCES INC compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 201% points. The greatest weakness of ALIMERA SCIENCES INC is the variable Other Expenses, reducing the Economic Capital Ratio by 306% points.

The company's Economic Capital Ratio, given in the ranking table, is -171%, being 246% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	47,402
Cost of Goods Sold	0
Intangible Assets	20,604
Liabilities, Current	9,123
Liabilities, Non-Current	0
Other Assets	436
Other Compr. Net Income	-124
Other Expenses	39,892
Other Liabilities	0
Other Net Income	23
Property and Equipment	1,787
Research and Development	12,375
Revenues	34,333
Selling, General and Administrative Expense	15,263

Output Variable	Value in 1000 USD
Assets	70,229
Liabilities	9,123
Expenses	67,530
Stockholders Equity	61,106
Net Income	-33,174
Comprehensive Net Income	-33,236
Economic Capital Ratio	-171%